None listed
Conditions
Brief summary
This project aims to compare a complex care model, the Victorian Comprehensive Parkinson’s Disease Program (VCPP) with usual care (conventional care), to determine which caters best for the complexity and cumulative morbidity over time of people with Parkinson’s disease (PD) and at what cost. A quasi-experimental trial will be conducted in the Melbourne metropolitan region incorporating an economic analysis alongside the clinical trial. 180 people with PD will be recruited from referrals to the VCPP (intervention group), or to the Monash Medical Centre Neurology Department (control group). Participants will be seen at four times (baseline, 1 year, 2 years and 3 years) following recruitment into the study. The long term follow-up is required to encompass the effects of natural deterioration with PD and ageing. In addition, participants will be contacted by telephone at 6 months, 18 months and 30 months to encourage completion of the health service utilization and falls questionnaire. The primary outcome is quality of life, which will be measured using the PDQ39 form. We will also measure other aspects of impairment, functioning and participation. The cost analysis will include information on participants’ primary health care visits, medication type and usage, hospitalizations and length of stay, episodes of inpatient rehabilitation care and aged care institutional care. This data will be collected using the health service utilization questionnaire and Medicare Australia data. Optimal management of the complexity of the condition is important to the person with PD and their family, and the detainment of costs is important for health systems (private and public), governing authorities and support organizations. The findings of this report have the potential to determine if the comprehensive care model is more cost effective for management of PD from a health system perspective. The implications would then have the capacity to revolutionize care for people with PD.
Interventions
The Victorian Comprehensive Parkinson’s Program (VCPP) is an alternative care model that involves an inter-professional team approach to the management of the complex array of motor and non motor symptoms that occur with PD.Treatment aims to limit the rate and level of progression and to provide strategies to enable people to compensate for their impairments so that people with PD and others in their lives can enjoy the highest possible quality of life.
The overall duration of the data collectio
The Victorian Comprehensive Parkinson’s Program (VCPP) is an alternative care model that involves an inter-professional team approach to the management of the complex array of motor and non motor symptoms that occur with PD.Treatment aims to limit the rate and level of progression and to provide strategies to enable people to compensate for their impairments so that people with PD and others in their lives can enjoy the highest possible quality of life. The overall duration of the data collection for the project will be over four years/48 months.
Sponsors
Southern Health
Study design
Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator)
Eligibility
Sex/Gender
All
Age
21 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
A diagnosis of idiopathic PD by a neurologist Living in the community Aged 21-85 years Hoehn & Yahr stage 1-1V (24) Provision of informed consent, including permission to access Medicare Australia data and hospital records from participating healthcare facilities Ability to travel to assessment clinics or consent to be assessed in their home Care giver participation in case of cognitive impairment (MMSE < 24/30) Be capable of completing study questionnaires over 3 year period alone, or with assistance from another person.
Exclusion criteria
Are unable to communicate in English as it is not feasible to provide interpreters Hoehn-Yahr Stage V or higher and non-ambulatory patients Unable or unwilling to provide informed consent Participation in a clinical (drug) trial
Outcome results
None listed